“Game Changing” technology enables QR code integration with 3D screen printing


DGAP-News: Laxxon Medical / Keyword(s): Miscellaneous
16.02.2022 / 11:50
The issuer is solely responsible for the content of this announcement.

NEW YORK, NY /ACCESSWIRE/ February 16, 2022 / A study published in the Biomedical Journal of Scientific & Technical Research (BJSTR) reports that advances in 3D screen printing enable mass personalization and labeling of pharmaceutical products with unique identifying information, such as quick response codes (QR), which have been shown to reduce medication errors, improve patient safety, and provide a viable mechanism for remote patient monitoring and identification of counterfeit drugs.

The study examines advances in the use of QR codes for drug labeling, with a particular focus on the potential for using 3D screen printing to accelerate the integration of QR codes at a single pill level .


3D screen-printed tablet with integrated QR code

Laxxon Medical Corp. holds the exclusive worldwide license to explore this 3DSP technology for all pharmaceutical applications.

“Using this approach, the QR code becomes part of a unique tablet manufacturing process,” said corresponding author Achim Schneeberger, PhD, CSO of Laxxon Medical. “3DSP could also be used to print APIs containing QR codes and/or inks that make the tablet easier to identify, harder to counterfeit, and increase product security.”

About Laxxon Medical Corporation

Laxxon Medical holds the exclusive worldwide rights to the patented use and application of 3D screen printing technology for the development, manufacturing and marketing of pharmaceutical dosage forms.

With Laxxon Medical’s innovative SPID(R) (Screen Printing Innovational Drug Technology) technology, it is possible for the first time to develop custom-release oral, transdermal and implantable dosage forms through geometric shaping and the heterogeneous distribution of active ingredients in the units.

Frances Hoggard, Public Relations Manager
[email protected]
THE SOURCE: Laxxon Medical

16.02.2022 Broadcast of a Corporate News, transmitted by the DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP distribution services include regulatory announcements, financial/corporate news and press releases.
Archive at www.dgap.de


Comments are closed.